Endometrioid carcinoma of the ovary: Retrospective review of 145 cases

Richard Kline, R C Kline, Kline RC, J. Taylor Wharton, Wharton JT, J T Wharton, Atkinson EN, E N Atkinson, E. Neely Atkinson, Burke TW, T W Burke, Thomas W. Burke, Gershenson DM, D. M. Gershenson, David M. Gershenson, C L Edwards, Creighton L. Edwards, Edwards CL
Gynecologic Oncology · 1990 · vol. 39(3) , pp. 337–346 · doi:10.1016/0090-8258(90)90263-k · PMID:2258081 · W2062262881
article OA: closed CC0 ⤵ 18 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-12 ⓘ

This retrospective review of 145 endometrioid ovarian carcinoma cases found that complete clinical response significantly improved median survival across all chemotherapy types, while chemotherapy regimens themselves did not show significant survival differences for advanced stages.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

From 1967 through December 1987, 145 patients with endometrioid carcinoma of the ovary were treated at the University of Texas M. D. Anderson Cancer Center. Thirty-eight patients (26.2%) had stage I disease, 28 (19.3%) stage II, 60 (41.4%) stage III, and 11 (7.6%) stage IV; 8 patients (5.5%) were unstaged. Grade 2 or 3 histology was seen in 119 patients (82.1%). In addition to surgical therapy, 128 patients underwent chemotherapy, including single-agent therapy, noncisplatin combination therapy, and cisplatin-based therapy. No statistically significant improvement in median survival was noted among these three chemotherapy groups for stages II, III, and IV (P = 0.22). A significant improvement in median survival was noted for those patients who achieved a complete clinical response, regardless of type of chemotherapy (96 or more months for single-agent therapy, P = 0.001; 31.5 months for noncisplatin combination therapy, P = 0.016; and 85 months for cisplatin-based therapy, P = 0.0001). Synchronous ovarian and uterine malignancies were seen in 18 patients (12.4%). No difference in survival was seen for patients with endometriosis (P = 0.13) or endometrial cancer (P = 0.09) when compared with those who did not have these histologic findings.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Endometriosis Endometriosis Endometriosis Endometriosis Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols Combined Modality Therapy Female Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (34)

Cited by (18)

Source provenance

europepmc
last seen: 2026-08-06T06:07:45.168820+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:12:05.481982+00:00
License: CC0 · commercial use OK